Curis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Curis, Inc. - overview
Established
2000
Location
Lexington, MA, US
Primary Industry
Biotechnology
About
Curis, Inc. is focused on the development and commercialization of therapeutics aimed at enhancing treatment outcomes for cancer patients, with a particular emphasis on hematologic malignancies. Curis, Inc. specializes in cancer therapeutics, founded in 2000 and headquartered in Lexington, US.
The company has undergone multiple business strategies and has participated in 4 funding deals. The most recent funding round raised USD 6. 00 mn. Tanvir Islam is the founder, while Jim Dentzer and Narek Oganyan are key executives leading the company.
Curis, Inc. focuses on the development and commercialization of innovative therapeutics designed to improve outcomes for cancer patients, particularly those facing hematologic malignancies. Their core product, Emavusertib (CA-4948), is aimed at addressing specific cancer types through targeted mechanisms. Alongside Emavusertib, the company has a pipeline that includes other investigational therapies such as Fimepinostat and CA-170, targeting various cancers like leukemia and lymphoma.
Curis's products are marketed primarily to healthcare providers, oncologists, and hospitals in the United States and select international markets. Curis, Inc. generates revenue through partnerships and collaborations that facilitate the commercialization of its therapeutic products. The company engages in licensing agreements with pharmaceutical partners, allowing revenue to be generated from milestone payments and royalties related to products such as Emavusertib.
Furthermore, funding from research grants aids in advancing clinical studies and bringing their therapeutics to market. Curis, Inc. plans to expand its product pipeline with upcoming launches of new therapies designed to treat specific cancer types in late 2024. The company is also targeting expansion into European and Asian markets by 2025.
The recent funding of USD 6. 00 mn will be utilized to support these initiatives and enhance their research capabilities. Additionally, Ew Healthcare Partners has acquired Curis, Inc. , further positioning the company for growth.
Current Investors
EW Healthcare Partners, Debiopharm Group
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.curis.com
Total Amount Raised
Subscriber access only
Curis, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Curis, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.